Literature DB >> 31210631

In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.

Anandi Martin1, Isabel Torres Godino1, Diana Angelica Aguilar-Ayala2, Vanessa Mathys3, Nacer Lounis4, Hector Rodriguez Villalobos1,5.   

Abstract

Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown. The objective of this study was to determine the in vitro activity of BDQ on SGM by assessing their MIC and minimal bactericidal concentration (MBC). The MIC of BDQ against 17 clinical isolates including Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium chimaera, Mycobacterium kansasii and Mycobacterium simiae species was determined by the resazurin microtitre assay and the MBC by the c.f.u. determination on 7H10 agar plates. BDQ has a bacteriostatic activity on all SGM tested with a MIC range from 0.03 to 0.007 µg ml-1 and surprisingly a good bactericidal activity on the majority of the isolates tested with an MBC of 1-2 µg ml-1 . Based on these preliminary results BDQ seems to be very promising for treatment of diseases caused by SGM.

Entities:  

Keywords:  bedaquiline; drug resistance; mycobacteria

Mesh:

Substances:

Year:  2019        PMID: 31210631     DOI: 10.1099/jmm.0.001025

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  5 in total

Review 1.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

2.  Searching for new therapeutic options for the uncommon pathogen Mycobacterium chimaera: an open drug discovery approach.

Authors:  Daire Cantillon; Aaron Goff; Stuart Taylor; Emad Salehi; Katy Fidler; Simon Stoneham; Simon J Waddell
Journal:  Lancet Microbe       Date:  2022-04-01

Review 3.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03

4.  Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV.

Authors:  Eliza Gil; Nicola Sweeney; Veronica Barrett; Stephen Morris-Jones; Robert F Miller; Victoria J Johnston; Michael Brown
Journal:  Emerg Infect Dis       Date:  2021-03       Impact factor: 6.883

5.  Population Pharmacokinetic Analysis of Bedaquiline-Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study.

Authors:  Ken Kurosawa; Stefaan Rossenu; Jeike Biewenga; Sivi Ouwerkerk-Mahadevan; Wouter Willems; Etienne Ernault; Chrispin Kambili
Journal:  J Clin Pharmacol       Date:  2021-06-12       Impact factor: 3.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.